CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression
Identifieur interne : 002136 ( Istex/Corpus ); précédent : 002135; suivant : 002137CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression
Auteurs : Bruno Aouizerate ; Ann Ho ; James H. Schluger ; Guillaume Perret ; Lisa Borg ; Michel Le Moal ; Pier V. Piazza ; Mary Jeanne KreekSource :
- Addiction Biology [ 1355-6215 ] ; 2006-03.
English descriptors
- KwdEn :
Abstract
Combined cocaine and illicit opiate use is common. This study aimed to test the hypothesis that cocaine dependence in former heroin‐addicted patients maintained on methadone treatment is associated with enhanced glucocorticoid negative feedback. Multiple dose dexamethasone suppression tests, using a conventional 2.0 mg dose, and two lower doses, 0.5 mg and 0.125 mg, were performed in 10 methadone‐maintained former heroin addicts with ongoing cocaine dependence (C‐MM), 10 stabilized methadone‐maintained former heroin addicts with no ongoing drug or alcohol use (MM), and 22 normal volunteers (NV). At 9 hours, there was no difference in plasma adrenocorticotropin hormone (ACTH) and/or cortisol levels among groups on the baseline day, as well as after the two lower doses of dexamethasone. At 17 hours, C‐MM and MM had significantly lower plasma ACTH and/or cortisol levels than NV. However, C‐MM did not significantly differ from MM in their hormonal levels. When the hormonal responses to dexamethasone are expressed as magnitude of lowering from baseline, there was no significant difference at any dose among groups. Therefore, C‐MM exhibited a normal glucocorticoid negative feedback in the morning. Using the standard interpretation of dexamethasone suppression testing based on the examination of the actual hormonal levels rather than the difference from baseline condition, C‐MM appear to have glucocorticoid effects similar to MM, yet were both greater than NV in the late afternoon. Thus, further studies are needed to know whether altered glucocorticoid negative feedback is related to chronic cocaine exposure, or is the result of former heroin addiction and/or its long‐term treatment with methadone.
Url:
DOI: 10.1111/j.1369-1600.2006.00006.x
Links to Exploration step
ISTEX:90C28DEEB05009163DD0B31065660D880FE3D508Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title><author><name sortKey="Aouizerate, Bruno" sort="Aouizerate, Bruno" uniqKey="Aouizerate B" first="Bruno" last="Aouizerate">Bruno Aouizerate</name><affiliation><mods:affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</mods:affiliation></affiliation></author><author><name sortKey="Ho, Ann" sort="Ho, Ann" uniqKey="Ho A" first="Ann" last="Ho">Ann Ho</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Schluger, James H" sort="Schluger, James H" uniqKey="Schluger J" first="James H." last="Schluger">James H. Schluger</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Perret, Guillaume" sort="Perret, Guillaume" uniqKey="Perret G" first="Guillaume" last="Perret">Guillaume Perret</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Borg, Lisa" sort="Borg, Lisa" uniqKey="Borg L" first="Lisa" last="Borg">Lisa Borg</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Le Moal, Michel" sort="Le Moal, Michel" uniqKey="Le Moal M" first="Michel" last="Le Moal">Michel Le Moal</name><affiliation><mods:affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</mods:affiliation></affiliation></author><author><name sortKey="Piazza, Pier V" sort="Piazza, Pier V" uniqKey="Piazza P" first="Pier V." last="Piazza">Pier V. Piazza</name><affiliation><mods:affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</mods:affiliation></affiliation></author><author><name sortKey="Kreek, Mary Jeanne" sort="Kreek, Mary Jeanne" uniqKey="Kreek M" first="Mary Jeanne" last="Kreek">Mary Jeanne Kreek</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: kreek@mail.rockefeller.edu</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:90C28DEEB05009163DD0B31065660D880FE3D508</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1369-1600.2006.00006.x</idno><idno type="url">https://api.istex.fr/document/90C28DEEB05009163DD0B31065660D880FE3D508/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002136</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002136</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title><author><name sortKey="Aouizerate, Bruno" sort="Aouizerate, Bruno" uniqKey="Aouizerate B" first="Bruno" last="Aouizerate">Bruno Aouizerate</name><affiliation><mods:affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</mods:affiliation></affiliation></author><author><name sortKey="Ho, Ann" sort="Ho, Ann" uniqKey="Ho A" first="Ann" last="Ho">Ann Ho</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Schluger, James H" sort="Schluger, James H" uniqKey="Schluger J" first="James H." last="Schluger">James H. Schluger</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Perret, Guillaume" sort="Perret, Guillaume" uniqKey="Perret G" first="Guillaume" last="Perret">Guillaume Perret</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Borg, Lisa" sort="Borg, Lisa" uniqKey="Borg L" first="Lisa" last="Borg">Lisa Borg</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation></author><author><name sortKey="Le Moal, Michel" sort="Le Moal, Michel" uniqKey="Le Moal M" first="Michel" last="Le Moal">Michel Le Moal</name><affiliation><mods:affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</mods:affiliation></affiliation></author><author><name sortKey="Piazza, Pier V" sort="Piazza, Pier V" uniqKey="Piazza P" first="Pier V." last="Piazza">Pier V. Piazza</name><affiliation><mods:affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</mods:affiliation></affiliation></author><author><name sortKey="Kreek, Mary Jeanne" sort="Kreek, Mary Jeanne" uniqKey="Kreek M" first="Mary Jeanne" last="Kreek">Mary Jeanne Kreek</name><affiliation><mods:affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: kreek@mail.rockefeller.edu</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Addiction Biology</title><idno type="ISSN">1355-6215</idno><idno type="eISSN">1369-1600</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2006-03">2006-03</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="84">84</biblScope><biblScope unit="page" to="96">96</biblScope></imprint><idno type="ISSN">1355-6215</idno></series><idno type="istex">90C28DEEB05009163DD0B31065660D880FE3D508</idno><idno type="DOI">10.1111/j.1369-1600.2006.00006.x</idno><idno type="ArticleID">ADB006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1355-6215</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cocaine addiction</term><term>dexamethasone supression testing</term><term>dose–response</term><term>glucocorticoid negative feedback</term><term>hypothalamic–pituitary–adrenal axis</term><term>methadone maintenance treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Combined cocaine and illicit opiate use is common. This study aimed to test the hypothesis that cocaine dependence in former heroin‐addicted patients maintained on methadone treatment is associated with enhanced glucocorticoid negative feedback. Multiple dose dexamethasone suppression tests, using a conventional 2.0 mg dose, and two lower doses, 0.5 mg and 0.125 mg, were performed in 10 methadone‐maintained former heroin addicts with ongoing cocaine dependence (C‐MM), 10 stabilized methadone‐maintained former heroin addicts with no ongoing drug or alcohol use (MM), and 22 normal volunteers (NV). At 9 hours, there was no difference in plasma adrenocorticotropin hormone (ACTH) and/or cortisol levels among groups on the baseline day, as well as after the two lower doses of dexamethasone. At 17 hours, C‐MM and MM had significantly lower plasma ACTH and/or cortisol levels than NV. However, C‐MM did not significantly differ from MM in their hormonal levels. When the hormonal responses to dexamethasone are expressed as magnitude of lowering from baseline, there was no significant difference at any dose among groups. Therefore, C‐MM exhibited a normal glucocorticoid negative feedback in the morning. Using the standard interpretation of dexamethasone suppression testing based on the examination of the actual hormonal levels rather than the difference from baseline condition, C‐MM appear to have glucocorticoid effects similar to MM, yet were both greater than NV in the late afternoon. Thus, further studies are needed to know whether altered glucocorticoid negative feedback is related to chronic cocaine exposure, or is the result of former heroin addiction and/or its long‐term treatment with methadone.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Bruno Aouizerate</name><affiliations><json:string>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</json:string></affiliations></json:item><json:item><name>Ann Ho</name><affiliations><json:string>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</json:string></affiliations></json:item><json:item><name>James H. Schluger</name><affiliations><json:string>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</json:string></affiliations></json:item><json:item><name>Guillaume Perret</name><affiliations><json:string>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</json:string></affiliations></json:item><json:item><name>Lisa Borg</name><affiliations><json:string>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</json:string></affiliations></json:item><json:item><name>Michel Le Moal</name><affiliations><json:string>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</json:string></affiliations></json:item><json:item><name>Pier V. Piazza</name><affiliations><json:string>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</json:string></affiliations></json:item><json:item><name>Mary Jeanne Kreek</name><affiliations><json:string>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</json:string><json:string>E-mail: kreek@mail.rockefeller.edu</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Cocaine addiction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>methadone maintenance treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hypothalamic–pituitary–adrenal axis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>glucocorticoid negative feedback</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dexamethasone supression testing</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dose–response</value></json:item></subject><articleId><json:string>ADB006</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Combined cocaine and illicit opiate use is common. This study aimed to test the hypothesis that cocaine dependence in former heroin‐addicted patients maintained on methadone treatment is associated with enhanced glucocorticoid negative feedback. Multiple dose dexamethasone suppression tests, using a conventional 2.0 mg dose, and two lower doses, 0.5 mg and 0.125 mg, were performed in 10 methadone‐maintained former heroin addicts with ongoing cocaine dependence (C‐MM), 10 stabilized methadone‐maintained former heroin addicts with no ongoing drug or alcohol use (MM), and 22 normal volunteers (NV). At 9 hours, there was no difference in plasma adrenocorticotropin hormone (ACTH) and/or cortisol levels among groups on the baseline day, as well as after the two lower doses of dexamethasone. At 17 hours, C‐MM and MM had significantly lower plasma ACTH and/or cortisol levels than NV. However, C‐MM did not significantly differ from MM in their hormonal levels. When the hormonal responses to dexamethasone are expressed as magnitude of lowering from baseline, there was no significant difference at any dose among groups. Therefore, C‐MM exhibited a normal glucocorticoid negative feedback in the morning. Using the standard interpretation of dexamethasone suppression testing based on the examination of the actual hormonal levels rather than the difference from baseline condition, C‐MM appear to have glucocorticoid effects similar to MM, yet were both greater than NV in the late afternoon. Thus, further studies are needed to know whether altered glucocorticoid negative feedback is related to chronic cocaine exposure, or is the result of former heroin addiction and/or its long‐term treatment with methadone.</abstract><qualityIndicators><score>8.488</score><pdfVersion>1.4</pdfVersion><pdfPageSize>595 x 782 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1720</abstractCharCount><pdfWordCount>7549</pdfWordCount><pdfCharCount>46814</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>249</abstractWordCount></qualityIndicators><title>CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title><refBibs><json:item><author><json:item><name>DC Aron</name></json:item></author><host><pages><last>1670</last><first>1655</first></pages><author></author><title>Endocrinology</title></host><title>Diagnostic implications of adrenal physiology and clinical epidemiology for evaluation of glucocorticoid excess and deficiency</title></json:item><json:item><author><json:item><name>GM Asnis</name></json:item><json:item><name>EJ Sachar</name></json:item><json:item><name>U Halbreich</name></json:item><json:item><name>RS Nathan</name></json:item><json:item><name>L Ostrow</name></json:item><json:item><name>FS Halpern</name></json:item></author><host><volume>138</volume><pages><last>1221</last><first>1218</first></pages><author></author><title>Am J Psychiatry</title></host><title>Cortisol secretion and dexamethasone response in depression</title></json:item><json:item><author><json:item><name>MH Baumann</name></json:item><json:item><name>TM Gendron</name></json:item><json:item><name>KM Becketts</name></json:item><json:item><name>JE Henningfield</name></json:item><json:item><name>DA Gorelick</name></json:item><json:item><name>RB Rothman</name></json:item></author><host><volume>38</volume><pages><last>755</last><first>751</first></pages><author></author><title>Biol Psychiatry</title></host><title>Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers</title></json:item><json:item><author><json:item><name>AT Beck</name></json:item><json:item><name>RA Steer</name></json:item><json:item><name>MG Garbin</name></json:item></author><host><volume>8</volume><pages><last>100</last><first>77</first></pages><author></author><title>Clin Psychol Rev</title></host><title>Psychometric properties of the Beck depression inventory: twenty five years of evaluation</title></json:item><json:item><author><json:item><name>AT Beck</name></json:item><json:item><name>CH Ward</name></json:item><json:item><name>M Mendelson</name></json:item><json:item><name>J Mock</name></json:item><json:item><name>J Erbaugh</name></json:item></author><host><volume>4</volume><pages><last>571</last><first>561</first></pages><author></author><title>Arch Gen Psychiatry</title></host><title>An inventory for measuring depression</title></json:item><json:item><author><json:item><name>A Biglino</name></json:item><json:item><name>P Limone</name></json:item><json:item><name>B Forno</name></json:item><json:item><name>A Pollono</name></json:item><json:item><name>G Cariti</name></json:item><json:item><name>GM Molinatti</name></json:item><json:item><name>P Gioannini</name></json:item></author><host><volume>133</volume><pages><last>179</last><first>173</first></pages><author></author><title>Eur J Endocrinol</title></host><title>Altered adrenocorticotropin and cortisol response to corticotropin‐releasing hormone in HIV‐1 infection</title></json:item><json:item><author><json:item><name>L Borg</name></json:item><json:item><name>A Ho</name></json:item><json:item><name>JE Peters</name></json:item><json:item><name>MJ Kreek</name></json:item></author><host><volume>14</volume><pages><last>96</last><first>83</first></pages><author></author><title>J Addict Dis</title></host><title>Availability of reliable serum methadone determination for management of symptomatic patients</title></json:item><json:item><author><json:item><name>L Buydens‐Branchey</name></json:item><json:item><name>M Branchey</name></json:item><json:item><name>J Hudson</name></json:item><json:item><name>M Dorota Majewska</name></json:item></author><host><volume>27</volume><pages><last>97</last><first>83</first></pages><author></author><title>Psychoneuroendocrinology</title></host><title>Perturbations of plasma cortisol and DHEA‐S following discontinuation of cocaine use in cocaine addicts</title></json:item><json:item><author><json:item><name>BJ Carroll</name></json:item><json:item><name>M Feinberg</name></json:item><json:item><name>JF Greden</name></json:item><json:item><name>J Tarika</name></json:item><json:item><name>AA Albala</name></json:item><json:item><name>RF Haskett</name></json:item><json:item><name>NM James</name></json:item><json:item><name>Z Kronfol</name></json:item><json:item><name>N Lohr</name></json:item><json:item><name>M Steiner</name></json:item><json:item><name>JP De Vigne</name></json:item><json:item><name>E Young</name></json:item></author><host><volume>38</volume><pages><last>22</last><first>15</first></pages><author></author><title>Arch Gen Psychiatry</title></host><title>A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility</title></json:item><json:item><author><json:item><name>F Cassidy</name></json:item><json:item><name>JC Ritchie</name></json:item><json:item><name>K Verghese</name></json:item><json:item><name>BJ Carroll</name></json:item></author><host><volume>47</volume><pages><last>680</last><first>677</first></pages><author></author><title>Biol Psychiatry</title></host><title>Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors</title></json:item><json:item><author><json:item><name>JA Culpepper‐Morgan</name></json:item><json:item><name>MJ Kreek</name></json:item></author><host><volume>46</volume><pages><last>134</last><first>130</first></pages><author></author><title>Metabolism</title></host><title>Hypothalamic‐pituitary‐adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone‐induced withdrawal</title></json:item><json:item><author><json:item><name>FH Gawin</name></json:item><json:item><name>HD Kleber</name></json:item></author><host><volume>43</volume><pages><last>113</last><first>107</first></pages><author></author><title>Arch Gen Psychiatry</title></host><title>Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations</title></json:item><json:item><author><json:item><name>CE Inturrisi</name></json:item><json:item><name>K Verebely</name></json:item></author><host><volume>13</volume><pages><last>637</last><first>633</first></pages><author></author><title>Clin Pharmacol Ther</title></host><title>The levels of methadone in the plasma in methadone maintenance</title></json:item><json:item><author><json:item><name>C Iribarne</name></json:item><json:item><name>F Berthou</name></json:item><json:item><name>S Baird</name></json:item><json:item><name>Y Dreano</name></json:item><json:item><name>D Picart</name></json:item><json:item><name>JP Bail</name></json:item><json:item><name>P Beaune</name></json:item><json:item><name>JF Menez</name></json:item></author><host><volume>9</volume><pages><last>373</last><first>365</first></pages><author></author><title>Chem Res Toxicol</title></host><title>Involvement of cytochrome P450 3A4 enzyme in the N‐demethylation of methadone in human liver microsomes</title></json:item><json:item><author><json:item><name>MA Kling</name></json:item><json:item><name>RE Carson</name></json:item><json:item><name>L Borg</name></json:item><json:item><name>A Zametkin</name></json:item><json:item><name>JA Matochik</name></json:item><json:item><name>J Schluger</name></json:item><json:item><name>P Herscovitch</name></json:item><json:item><name>KC Rice</name></json:item><json:item><name>A Ho</name></json:item><json:item><name>WC Eckelman</name></json:item><json:item><name>MJ Kreek</name></json:item></author><host><volume>295</volume><pages><last>1076</last><first>1070</first></pages><author></author><title>J Pharmacol Exp Ther</title></host><title>Opioid receptor imaging with positron emission tomography and [18F]cyclofoxy in long‐term, methadone‐treated former heroin addicts</title></json:item><json:item><author><json:item><name>M Koehl</name></json:item><json:item><name>V Lemaire</name></json:item><json:item><name>W Mayo</name></json:item><json:item><name>DN Abrous</name></json:item><json:item><name>S Maccari</name></json:item><json:item><name>PV Piazza</name></json:item><json:item><name>M Le Moal</name></json:item><json:item><name>M Vallee</name></json:item></author><host><volume>4</volume><pages><last>296</last><first>281</first></pages><author></author><title>Neurotox Res</title></host><title>Individual vulnerability to substance abuse and affective disorders: role of early environmental influences</title></json:item><json:item><host><author></author><title>Medical safety, side effects and toxicity of methadoneProceedings of the Fourth National Conference on Methadone Treatment.</title></host></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item></author><host><volume>223</volume><pages><last>668</last><first>665</first></pages><author></author><title>JAMA</title></host><title>Medical safety and side effects of methadone in tolerant individuals</title></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item></author><host><volume>73</volume><pages><last>2777</last><first>2773</first></pages><author></author><title>NY State J Med</title></host><title>Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment</title></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item></author><host><pages><last>1604</last><first>1597</first></pages><author></author><title>Psychopharmacology: the Third Generation in Progress</title></host><title>Multiple drug abuse patterns and medical consequences</title></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item></author><host><pages><last>230</last><first>205</first></pages><author></author><title>Addictive States</title></host><title>Rationale for maintenance pharmacotherapy of opiate dependence</title></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item><json:item><name>KS LaForge</name></json:item><json:item><name>E Butelman</name></json:item></author><host><volume>1</volume><pages><last>726</last><first>710</first></pages><author></author><title>Nat Rev Drug Discov</title></host><title>Pharmacotherapy of addictions</title></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item><json:item><name>J Raghunath</name></json:item><json:item><name>S Plevy</name></json:item><json:item><name>D Hamer</name></json:item><json:item><name>B Schneider</name></json:item><json:item><name>N Hartman</name></json:item></author><host><volume>5</volume><pages><last>278</last><first>277</first></pages><author></author><title>Neuropeptides</title></host><title>ACTH, cortisol and beta‐endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans</title></json:item><json:item><author><json:item><name>MJ Kreek</name></json:item><json:item><name>SL Wardlaw</name></json:item><json:item><name>N Hartman</name></json:item><json:item><name>J Raghunath</name></json:item><json:item><name>J Friedman</name></json:item><json:item><name>B Schneider</name></json:item><json:item><name>AG Frantz</name></json:item></author><host><volume>33</volume><pages><last>411</last><first>409</first></pages><author></author><title>Life Sci</title></host><title>Circadian rhythms and levels of beta‐endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans</title></json:item><json:item><author><json:item><name>RD Levitan</name></json:item><json:item><name>NA Rector</name></json:item><json:item><name>T Sheldon</name></json:item><json:item><name>P Goering</name></json:item></author><host><volume>17</volume><pages><last>42</last><first>34</first></pages><author></author><title>Depress Anxiety</title></host><title>Childhood adversities associated with major depression and/or anxiety disorders in a community sample of Ontario: issues of co‐morbidity and specificity</title></json:item><json:item><author><json:item><name>GW Liddle</name></json:item></author><host><volume>20</volume><pages><last>1560</last><first>1539</first></pages><author></author><title>J Clin Endocrinol Metab</title></host><title>Tests of pituitary‐adrenal suppressibility in the diagnosis of Cushing’s syndrome</title></json:item><json:item><author><json:item><name>C Liddle</name></json:item><json:item><name>BJ Goodwin</name></json:item><json:item><name>J George</name></json:item><json:item><name>M Tapner</name></json:item><json:item><name>GC Farrell</name></json:item></author><host><volume>83</volume><pages><last>2416</last><first>2411</first></pages><author></author><title>J Clin Endocrinol Metab</title></host><title>Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes</title></json:item><json:item><author><json:item><name>D Loew</name></json:item><json:item><name>O Schuster</name></json:item><json:item><name>EH Graul</name></json:item></author><host><volume>30</volume><pages><last>230</last><first>225</first></pages><author></author><title>Eur J Clin Pharmacol</title></host><title>Dose‐dependent pharmacokinetics of dexamethasone</title></json:item><json:item><author><json:item><name>G Luo</name></json:item><json:item><name>M Cunningham</name></json:item><json:item><name>S Kim</name></json:item><json:item><name>T Burn</name></json:item><json:item><name>J Lin</name></json:item><json:item><name>M Sinz</name></json:item><json:item><name>G Hamilton</name></json:item><json:item><name>C Rizzo</name></json:item><json:item><name>S Jolley</name></json:item><json:item><name>D Gilbert</name></json:item><json:item><name>A Downey</name></json:item><json:item><name>D Mudra</name></json:item><json:item><name>R Graham</name></json:item><json:item><name>K Carroll</name></json:item><json:item><name>J Xie</name></json:item><json:item><name>A Madan</name></json:item><json:item><name>A Parkinson</name></json:item><json:item><name>D Christ</name></json:item><json:item><name>B Selling</name></json:item><json:item><name>E LeCluyse</name></json:item><json:item><name>LS Gan</name></json:item></author><host><volume>30</volume><pages><last>804</last><first>795</first></pages><author></author><title>Drug Metab Dispos</title></host><title>CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</title></json:item><json:item><author><json:item><name>CL Magnano</name></json:item><json:item><name>JM Gardner</name></json:item><json:item><name>BZ Karmel</name></json:item></author><host><volume>25</volume><pages><last>103</last><first>93</first></pages><author></author><title>Dev Psychobiol</title></host><title>Differences in salivary cortisol levels in cocaine‐exposed and noncocaine‐exposed NICU infants</title></json:item><json:item><author><json:item><name>JH Mendelson</name></json:item><json:item><name>M Sholar</name></json:item><json:item><name>NK Mello</name></json:item><json:item><name>SK Teoh</name></json:item><json:item><name>JW Sholar</name></json:item></author><host><volume>18</volume><pages><last>271</last><first>263</first></pages><author></author><title>Neuropsychopharmacology</title></host><title>Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men</title></json:item><json:item><author><json:item><name>JH Mendelson</name></json:item><json:item><name>SK Teoh</name></json:item><json:item><name>U Lange</name></json:item><json:item><name>NK Mello</name></json:item><json:item><name>R Weiss</name></json:item><json:item><name>A Skupny</name></json:item><json:item><name>J Ellingboe</name></json:item></author><host><volume>145</volume><pages><last>1098</last><first>1094</first></pages><author></author><title>Am J Psychiatry</title></host><title>Anterior pituitary, adrenal, and gonadal hormones during cocaine withdrawal</title></json:item><json:item><author><json:item><name>JH Mendelson</name></json:item><json:item><name>SK Teoh</name></json:item><json:item><name>NK Mello</name></json:item><json:item><name>J Ellingboe</name></json:item><json:item><name>E Rhoades</name></json:item></author><host><volume>263</volume><pages><last>509</last><first>505</first></pages><author></author><title>J Pharmacol Exp Ther</title></host><title>Acute effects of cocaine on plasma adrenocorticotropic hormone, luteinizing hormone and prolactin levels in cocaine‐dependent men</title></json:item><json:item><author><json:item><name>DE Moody</name></json:item><json:item><name>ME Alburges</name></json:item><json:item><name>RJ Parker</name></json:item><json:item><name>JM Collins</name></json:item><json:item><name>JM Strong</name></json:item></author><host><volume>25</volume><pages><last>1353</last><first>1347</first></pages><author></author><title>Drug Metab Dispos</title></host><title>The involvement of cytochrome P450 3A4 in the N‐demethylation of L‐alpha‐acetylmethadol (LAAM), norLAAM, and methadone</title></json:item><json:item><author><json:item><name>DN Nurco</name></json:item><json:item><name>TW Kinlock</name></json:item><json:item><name>KE O’Grady</name></json:item><json:item><name>TE Hanlon</name></json:item></author><host><volume>43</volume><pages><last>113</last><first>103</first></pages><author></author><title>Drug Alcohol Depend</title></host><title>Early family adversity as a precursor to narcotic addiction</title></json:item><json:item><author><json:item><name>JE Peters</name></json:item><json:item><name>JZ Chou</name></json:item><json:item><name>A Ho</name></json:item><json:item><name>K Reid</name></json:item><json:item><name>L Borg</name></json:item><json:item><name>MJ Kreek</name></json:item></author><host><volume>91</volume><pages><last>1697</last><first>1687</first></pages><author></author><title>Addiction</title></host><title>Simplified quantitation of urinary benzoylecgonine in cocaine addiction research and for related pharmacotherapeutic trials</title></json:item><json:item><author><json:item><name>PV Piazza</name></json:item><json:item><name>M Le Moal</name></json:item></author><host><volume>36</volume><pages><last>378</last><first>359</first></pages><author></author><title>Annu Rev Pharmacol Toxicol</title></host><title>Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons</title></json:item><json:item><author><json:item><name>PV Piazza</name></json:item><json:item><name>M Le Moal</name></json:item></author><host><volume>25</volume><pages><last>372</last><first>359</first></pages><author></author><title>Brain Res Brain Res Rev</title></host><title>Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications</title></json:item><json:item><author><json:item><name>MI Rosen</name></json:item><json:item><name>TJ McMahon</name></json:item><json:item><name>FA Hameedi</name></json:item><json:item><name>HR Pearsall</name></json:item><json:item><name>SW Woods</name></json:item><json:item><name>MJ Kreek</name></json:item><json:item><name>TR Kosten</name></json:item></author><host><volume>276</volume><pages><last>1135</last><first>1128</first></pages><author></author><title>J Pharmacol Exp Ther</title></host><title>Effect of clonidine pretreatment on naloxone‐precipitated opiate withdrawal</title></json:item><json:item><author><json:item><name>FA Scafidi</name></json:item><json:item><name>TM Field</name></json:item><json:item><name>A Wheeden</name></json:item><json:item><name>S Schanberg</name></json:item><json:item><name>C Kuhn</name></json:item><json:item><name>R Symanski</name></json:item><json:item><name>E Zimmerman</name></json:item><json:item><name>ES Bandstra</name></json:item></author><host><volume>97</volume><pages><last>855</last><first>851</first></pages><author></author><title>Pediatrics</title></host><title>Cocaine‐exposed preterm neonates show behavioral and hormonal differences</title></json:item><json:item><host><author></author><title>Abnormal metyrapone tests during cocaine abstinenceProblems of Drug Dependence, 1997. Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, National Institute of Drug Abuse Research Monograph Series.</title></host></json:item><json:item><author><json:item><name>JH Schluger</name></json:item><json:item><name>L Borg</name></json:item><json:item><name>A Ho</name></json:item><json:item><name>MJ Kreek</name></json:item></author><host><volume>24</volume><pages><last>575</last><first>568</first></pages><author></author><title>Neuropsychopharmacology</title></host><title>Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction</title></json:item><json:item><author><json:item><name>JH Schluger</name></json:item><json:item><name>A Ho</name></json:item><json:item><name>L Borg</name></json:item><json:item><name>M Porter</name></json:item><json:item><name>S Maniar</name></json:item><json:item><name>M Gunduz</name></json:item><json:item><name>G Perret</name></json:item><json:item><name>A King</name></json:item><json:item><name>MJ Kreek</name></json:item></author><host><volume>22</volume><pages><last>1436</last><first>1430</first></pages><author></author><title>Alcohol Clin Exp Res</title></host><title>Nalmefene causes greater hypothalamic‐pituitary‐adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism</title></json:item><json:item><author><json:item><name>RJ Turner</name></json:item><json:item><name>DA Lloyd</name></json:item></author><host><volume>98</volume><pages><last>315</last><first>305</first></pages><author></author><title>Addiction</title></host><title>Cumulative adversity and drug dependence in young adults: racial/ethnic contrasts</title></json:item><json:item><author><json:item><name>PP Vescovi</name></json:item><json:item><name>V Coiro</name></json:item><json:item><name>R Volpi</name></json:item><json:item><name>A Giannini</name></json:item><json:item><name>M Passeri</name></json:item></author><host><volume>15</volume><pages><last>675</last><first>671</first></pages><author></author><title>J Endocrinol Invest</title></host><title>Hyperthermia in sauna is unable to increase the plasma levels of ACTH/cortisol, beta‐endorphin and prolactin in cocaine addicts</title></json:item><json:item><author><json:item><name>PP Vescovi</name></json:item><json:item><name>V Coiro</name></json:item><json:item><name>R Volpi</name></json:item><json:item><name>M Passeri</name></json:item></author><host><volume>37</volume><pages><last>224</last><first>221</first></pages><author></author><title>Horm Res</title></host><title>Diurnal variations in plasma ACTH, cortisol and beta‐endorphin levels in cocaine addicts</title></json:item><json:item><author><json:item><name>WW Weddington</name></json:item><json:item><name>BS Brown</name></json:item><json:item><name>CA Haertzen</name></json:item><json:item><name>EJ Cone</name></json:item><json:item><name>EM Dax</name></json:item><json:item><name>RI Herning</name></json:item><json:item><name>BS Michaelson</name></json:item></author><host><volume>47</volume><pages><last>868</last><first>861</first></pages><author></author><title>Arch Gen Psychiatry</title></host><title>Changes in mood, craving, and sleep during short‐term abstinence reported by male cocaine addicts. A controlled, residential study</title></json:item><json:item><author><json:item><name>JN Wilkins</name></json:item><json:item><name>DA Gorelick</name></json:item><json:item><name>K Nademanee</name></json:item><json:item><name>A Taylor</name></json:item><json:item><name>DS Herzberg</name></json:item></author><host><volume>10</volume><pages><last>71</last><first>57</first></pages><author></author><title>Recent Dev Alcohol</title></host><title>Hypothalamic‐pituitary function during alcohol exposure and withdrawal and cocaine exposure</title></json:item><json:item><author><json:item><name>R Yehuda</name></json:item><json:item><name>D Boisoneau</name></json:item><json:item><name>MT Lowy</name></json:item><json:item><name>EL Giller</name></json:item></author><host><volume>52</volume><pages><last>593</last><first>583</first></pages><author></author><title>Arch Gen Psychiatry</title></host><title>Dose–response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder</title></json:item><json:item><author><json:item><name>R Yehuda</name></json:item><json:item><name>SM Southwick</name></json:item><json:item><name>JH Krystal</name></json:item><json:item><name>D Bremner</name></json:item><json:item><name>DS Charney</name></json:item><json:item><name>J Mason</name></json:item></author><host><volume>150</volume><pages><last>86</last><first>83</first></pages><author></author><title>Am J Psychiatry</title></host><title>Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder</title></json:item><json:item><author><json:item><name>W Zhang</name></json:item><json:item><name>A Purchio</name></json:item><json:item><name>K Chen</name></json:item><json:item><name>SM Burns</name></json:item><json:item><name>CH Contag</name></json:item><json:item><name>PR Contag</name></json:item></author><host><volume>65</volume><pages><last>1896</last><first>1889</first></pages><author></author><title>Biochem Pharmacol</title></host><title>In vivo activation of the human CYP3A4 promoter in mouse liver and regulation by pregnane X receptors</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>11</volume><publisherId><json:string>ADB</json:string></publisherId><pages><total>13</total><last>96</last><first>84</first></pages><issn><json:string>1355-6215</json:string></issn><issue>1</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1369-1600</json:string></eissn><title>Addiction Biology</title><doi><json:string>10.1111/(ISSN)1369-1600</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>substance abuse</json:string><json:string>science</json:string><json:string>biochemistry & molecular biology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>public health & health services</json:string><json:string>substance abuse</json:string></scienceMetrix></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1111/j.1369-1600.2006.00006.x</json:string></doi><id>90C28DEEB05009163DD0B31065660D880FE3D508</id><score>0.119940504</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/90C28DEEB05009163DD0B31065660D880FE3D508/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/90C28DEEB05009163DD0B31065660D880FE3D508/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/90C28DEEB05009163DD0B31065660D880FE3D508/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title><author xml:id="author-1"><persName><forename type="first">Bruno</forename><surname>Aouizerate</surname></persName><affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</affiliation></author><author xml:id="author-2"><persName><forename type="first">Ann</forename><surname>Ho</surname></persName><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">James H.</forename><surname>Schluger</surname></persName><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation></author><author xml:id="author-4"><persName><forename type="first">Guillaume</forename><surname>Perret</surname></persName><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation></author><author xml:id="author-5"><persName><forename type="first">Lisa</forename><surname>Borg</surname></persName><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation></author><author xml:id="author-6"><persName><forename type="first">Michel</forename><surname>Le Moal</surname></persName><affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</affiliation></author><author xml:id="author-7"><persName><forename type="first">Pier V.</forename><surname>Piazza</surname></persName><affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</affiliation></author><author xml:id="author-8"><persName><forename type="first">Mary Jeanne</forename><surname>Kreek</surname></persName><email>kreek@mail.rockefeller.edu</email><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation></author></analytic><monogr><title level="j">Addiction Biology</title><idno type="pISSN">1355-6215</idno><idno type="eISSN">1369-1600</idno><idno type="DOI">10.1111/(ISSN)1369-1600</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2006-03"></date><biblScope unit="volume">11</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="84">84</biblScope><biblScope unit="page" to="96">96</biblScope></imprint></monogr><idno type="istex">90C28DEEB05009163DD0B31065660D880FE3D508</idno><idno type="DOI">10.1111/j.1369-1600.2006.00006.x</idno><idno type="ArticleID">ADB006</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Combined cocaine and illicit opiate use is common. This study aimed to test the hypothesis that cocaine dependence in former heroin‐addicted patients maintained on methadone treatment is associated with enhanced glucocorticoid negative feedback. Multiple dose dexamethasone suppression tests, using a conventional 2.0 mg dose, and two lower doses, 0.5 mg and 0.125 mg, were performed in 10 methadone‐maintained former heroin addicts with ongoing cocaine dependence (C‐MM), 10 stabilized methadone‐maintained former heroin addicts with no ongoing drug or alcohol use (MM), and 22 normal volunteers (NV). At 9 hours, there was no difference in plasma adrenocorticotropin hormone (ACTH) and/or cortisol levels among groups on the baseline day, as well as after the two lower doses of dexamethasone. At 17 hours, C‐MM and MM had significantly lower plasma ACTH and/or cortisol levels than NV. However, C‐MM did not significantly differ from MM in their hormonal levels. When the hormonal responses to dexamethasone are expressed as magnitude of lowering from baseline, there was no significant difference at any dose among groups. Therefore, C‐MM exhibited a normal glucocorticoid negative feedback in the morning. Using the standard interpretation of dexamethasone suppression testing based on the examination of the actual hormonal levels rather than the difference from baseline condition, C‐MM appear to have glucocorticoid effects similar to MM, yet were both greater than NV in the late afternoon. Thus, further studies are needed to know whether altered glucocorticoid negative feedback is related to chronic cocaine exposure, or is the result of former heroin addiction and/or its long‐term treatment with methadone.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Cocaine addiction</term></item><item><term>methadone maintenance treatment</term></item><item><term>hypothalamic–pituitary–adrenal axis</term></item><item><term>glucocorticoid negative feedback</term></item><item><term>dexamethasone supression testing</term></item><item><term>dose–response</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/90C28DEEB05009163DD0B31065660D880FE3D508/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1369-1600</doi><issn type="print">1355-6215</issn><issn type="electronic">1369-1600</issn><idGroup><id type="product" value="ADB"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ADDICTION BIOLOGY">Addiction Biology</title></titleGroup></publicationMeta><publicationMeta level="part" position="03101"><doi origin="wiley">10.1111/adb.2006.11.issue-1</doi><numberingGroup><numbering type="journalVolume" number="11">11</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="2006-03">March 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley">10.1111/j.1369-1600.2006.00006.x</doi><idGroup><id type="unit" value="ADB006"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="tocHeading1">CLINICAL AND IMAGING STUDIES</title></titleGroup><eventGroup><event type="firstOnline" date="2006-06-07"></event><event type="publishedOnlineFinalForm" date="2006-06-07"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.17 mode:FullText source:FullText result:FullText" date="2010-09-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2013-12-31"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="84">84</numbering><numbering type="pageLast" number="96">96</numbering></numberingGroup><correspondenceTo>Mary Jeanne Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA. E‐mail: <email>kreek@mail.rockefeller.edu</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ADB.ADB006.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="1"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="51"></count><count type="wordTotal" number="8042"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title><title type="shortAuthors">Bruno Aouizerate <i>et al.</i></title><title type="short">Glucocorticoid negative feedback in C‐MM</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Bruno</givenNames><familyName>Aouizerate</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Ann</givenNames><familyName>Ho</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><givenNames>James H.</givenNames><familyName>Schluger</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a2"><personName><givenNames>Guillaume</givenNames><familyName>Perret</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a2"><personName><givenNames>Lisa</givenNames><familyName>Borg</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>Michel</givenNames><familyName>Le Moal</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a1"><personName><givenNames>Pier V.</givenNames><familyName>Piazza</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a2" corresponding="yes"><personName><givenNames>Mary Jeanne</givenNames><familyName>Kreek</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="US"><unparsedAffiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Cocaine addiction</keyword><keyword xml:id="k2">methadone maintenance treatment</keyword><keyword xml:id="k3">hypothalamic–pituitary–adrenal axis</keyword><keyword xml:id="k4">glucocorticoid negative feedback</keyword><keyword xml:id="k5">dexamethasone supression testing</keyword><keyword xml:id="k6">dose–response</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">ABSTRACT</title><p>Combined cocaine and illicit opiate use is common. This study aimed to test the hypothesis that cocaine dependence in former heroin‐addicted patients maintained on methadone treatment is associated with enhanced glucocorticoid negative feedback. Multiple dose dexamethasone suppression tests, using a conventional 2.0 mg dose, and two lower doses, 0.5 mg and 0.125 mg, were performed in 10 methadone‐maintained former heroin addicts with ongoing cocaine dependence (C‐MM), 10 stabilized methadone‐maintained former heroin addicts with no ongoing drug or alcohol use (MM), and 22 normal volunteers (NV). At 9 hours, there was no difference in plasma adrenocorticotropin hormone (ACTH) and/or cortisol levels among groups on the baseline day, as well as after the two lower doses of dexamethasone. At 17 hours, C‐MM and MM had significantly lower plasma ACTH and/or cortisol levels than NV. However, C‐MM did not significantly differ from MM in their hormonal levels. When the hormonal responses to dexamethasone are expressed as magnitude of lowering from baseline, there was no significant difference at any dose among groups. Therefore, C‐MM exhibited a normal glucocorticoid negative feedback in the morning. Using the standard interpretation of dexamethasone suppression testing based on the examination of the actual hormonal levels rather than the difference from baseline condition, C‐MM appear to have glucocorticoid effects similar to MM, yet were both greater than NV in the late afternoon. Thus, further studies are needed to know whether altered glucocorticoid negative feedback is related to chronic cocaine exposure, or is the result of former heroin addiction and/or its long‐term treatment with methadone.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Glucocorticoid negative feedback in C‐MM</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression</title></titleInfo><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Aouizerate</namePart><affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ann</namePart><namePart type="family">Ho</namePart><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James H.</namePart><namePart type="family">Schluger</namePart><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guillaume</namePart><namePart type="family">Perret</namePart><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lisa</namePart><namePart type="family">Borg</namePart><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michel</namePart><namePart type="family">Le Moal</namePart><affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pier V.</namePart><namePart type="family">Piazza</namePart><affiliation>Laboratory of Pathophysiology of Behavior, The Victor Segalen’s University (Bordeaux 2), France and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mary Jeanne</namePart><namePart type="family">Kreek</namePart><affiliation>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, USA</affiliation><affiliation>E-mail: kreek@mail.rockefeller.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2006-03</dateIssued><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">1</extent><extent unit="references">51</extent><extent unit="words">8042</extent></physicalDescription><abstract lang="en">Combined cocaine and illicit opiate use is common. This study aimed to test the hypothesis that cocaine dependence in former heroin‐addicted patients maintained on methadone treatment is associated with enhanced glucocorticoid negative feedback. Multiple dose dexamethasone suppression tests, using a conventional 2.0 mg dose, and two lower doses, 0.5 mg and 0.125 mg, were performed in 10 methadone‐maintained former heroin addicts with ongoing cocaine dependence (C‐MM), 10 stabilized methadone‐maintained former heroin addicts with no ongoing drug or alcohol use (MM), and 22 normal volunteers (NV). At 9 hours, there was no difference in plasma adrenocorticotropin hormone (ACTH) and/or cortisol levels among groups on the baseline day, as well as after the two lower doses of dexamethasone. At 17 hours, C‐MM and MM had significantly lower plasma ACTH and/or cortisol levels than NV. However, C‐MM did not significantly differ from MM in their hormonal levels. When the hormonal responses to dexamethasone are expressed as magnitude of lowering from baseline, there was no significant difference at any dose among groups. Therefore, C‐MM exhibited a normal glucocorticoid negative feedback in the morning. Using the standard interpretation of dexamethasone suppression testing based on the examination of the actual hormonal levels rather than the difference from baseline condition, C‐MM appear to have glucocorticoid effects similar to MM, yet were both greater than NV in the late afternoon. Thus, further studies are needed to know whether altered glucocorticoid negative feedback is related to chronic cocaine exposure, or is the result of former heroin addiction and/or its long‐term treatment with methadone.</abstract><subject lang="en"><genre>keywords</genre><topic>Cocaine addiction</topic><topic>methadone maintenance treatment</topic><topic>hypothalamic–pituitary–adrenal axis</topic><topic>glucocorticoid negative feedback</topic><topic>dexamethasone supression testing</topic><topic>dose–response</topic></subject><relatedItem type="host"><titleInfo><title>Addiction Biology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">1355-6215</identifier><identifier type="eISSN">1369-1600</identifier><identifier type="DOI">10.1111/(ISSN)1369-1600</identifier><identifier type="PublisherID">ADB</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>84</start><end>96</end><total>13</total></extent></part></relatedItem><identifier type="istex">90C28DEEB05009163DD0B31065660D880FE3D508</identifier><identifier type="DOI">10.1111/j.1369-1600.2006.00006.x</identifier><identifier type="ArticleID">ADB006</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002136 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002136 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:90C28DEEB05009163DD0B31065660D880FE3D508
|texte= CLINICAL AND IMAGING STUDY: Glucocorticoid negative feedback in methadone‐maintained former heroin addicts with ongoing cocaine dependence: dose–response to dexamethasone suppression
}}
| This area was generated with Dilib version V0.6.29. |  |